A simulation study of control sampling methods for nested case-control studies of genetic and molecular biomarkers and prostate cancer progression

Cancer Epidemiology Biomarkers and Prevention

Volumn 18, Issue 3, 2009, Pages 706-711

  Wang, Ming Hsi ^a,b   Shugart, Yin Yao ^a   Cole, Stephen R ^a,c   Platz, Elizabeth A ^a,d,e  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b ST AGNES HOSPITAL   (United States)

^c The University of North Carolina at Chapel Hill   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; MOLECULAR MARKER; TUMOR MARKER;

ARTICLE; CANCER GROWTH; CANCER INCIDENCE; CANCER PATIENT; CANCER RISK; CASE CONTROL STUDY; CONTENT VALIDITY; CONTROLLED STUDY; DISEASE SIMULATION; FOLLOW UP; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; MARKER GENE; MONTE CARLO METHOD; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RISK ASSESSMENT; RISK FACTOR; SAMPLING ERROR; DISEASE COURSE; EPIDEMIOLOGY; GENETICS; GENOTYPE; HUMAN; INCIDENCE; MALE; METHODOLOGY; PROSTATE TUMOR; STATISTICAL MODEL;

BIAS (EPIDEMIOLOGY); CASE-CONTROL STUDIES; DISEASE PROGRESSION; EPIDEMIOLOGIC METHODS; GENETIC VARIATION; GENOTYPE; HUMANS; INCIDENCE; LOGISTIC MODELS; MALE; MONTE CARLO METHOD; PROSTATIC NEOPLASMS; RESEARCH DESIGN; RISK ASSESSMENT; SAMPLING STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 64549114613     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-08-0839     Document Type: Article

References (20)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol 2004;172:910-914 (Pubitemid 39096421)
3. Han M, Partin A, Pound C, Epstein J, Walsh P. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy: the 15-year Johns Hopkins experience. Urol Clin North Am 2001;28:555-565 (Pubitemid 32916759)
4. Pound CR, Partin AW, Eisenberger MA, Chan EW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591-1597 (Pubitemid 29211767)
5. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998;90:766-771 (Pubitemid 28259189)
6. Michaud DS, Daugherty SE, Berndt SI, et al. Genetic polymorphisms of interleukin-1B (IL-1B), IL-6, IL-8, and IL-10 and risk of prostate cancer. Cancer Res 2006;66:4525-4530
7. Platz EA, Leitzmann MF, Rifai N, et al. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiol Biomarkers Prev 2005;14:1262-1269 (Pubitemid 40656478)
8. Hayes VM, Severi G, Padilla EJ, et al. 5A-Reductase type 2gene variant associations with prostate cancer risk, circulating hormone levels and androgenetic alopecia. Int J Cancer 2007;120:776-780 (Pubitemid 46175396)
9. Ernster VL. Nested case-control studies. Prev Med 1994;23:587-590 (Pubitemid 24377866)
10. Prentice RL. A case-cohort design for epidemiologic cohort studies and disease prevention trials. Biometrika 1986;73:1-11.
11. Prentice RL, Breslow NE. Retrospective studies and failure time models. Biometrika 1978;65:153-158 (Pubitemid 8308397)
12. Lubin JH, Gail MH. Biased selection of controls for case-control analyses of cohort studies. Biometrics 1984;40:63-75.
13. Robins JM, Gail MH, Lubin JH. More on "Biased selection of controls for case-control analyses of cohort studies." Biometrics 1986;42:293-299
14. Flanders WD, Louv WC. The exposure odds ratio in nested case-control studies with competing risks. Am J Epidemiol 1986;124:684-692 . (Pubitemid 17178252)
15. Visvanathan K, Helzlsouer KJ, Boorman DW, et al. Association among an ornithine decarboxylase polymorphism, androgen receptor gene (CAG) repeat length and prostate cancer risk. J Urol 2004;171:652-655 (Pubitemid 38090449)
16. Li H, Kantoff PW, Giovannucci E, et al. Manganese superoxide dismutase polymorphism, prediagnostic antioxidant status, and risk of clinical significant prostate cancer. Cancer Res 2005;65:2498-2504 (Pubitemid 40490163)
17. Allaf ME, Partin AW, Walsh PC. Who is cured? How long after radical prostatectomy can PSA rise? American Urological Association Annual Meeting; 2006.
18. Epstein JI, Partin AW, Sauvageot J, Walsh PC. Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up. Am J Surg Pathol 1996;20:286-292 (Pubitemid 26071509)
19. Pickle LW, Mungiole M, Jones GK, White AA. Atlas of United States mortality. Hyattsville (MD): National Center for Health Statistics; 1996.
20. Wacholder S, Gail M, Pee D. Selecting an efficient design for assessing exposure-disease relationships in an assembled cohort. Biometrics 1991;47:63-76.